Table 1 Clinical characteristics in gBRCA1/2 carriers and noncarriers

Number of patients

409 (100%)

337 (82%)

72 (18%)

Mean age at diagnosis (years)

47.62 ± 9.34

48.44 ± 9.20

43.78 ± 9.06

< 0.001

 Range

26–76

26–76

28–67

 < 40 years

91 (22.2%)

64 (19%)

27 (37.5%)

0.001

 ≥ 40 years

318 (77.8%)

273 (81%)

45 (62.5%)

With family history of any cancer

0.002

 No

374 (91.4%)

315 (93.5%)

59 (81.9%)

 Yes

35 (8.6%)

22 (6.5%)

13 (18.1%)

Laterality breast cancer

 Bilateral

20 (4.9%)

11 (3.3%)

9 (12.5%)

0.008

 Right

189 (46.2%)

162 (48.1%)

27 (37.5%)

 Left

200 (48.9%)

164 (48.7%)

36 (50%)

Invasive carcinoma

389 (95.1%)

320 (95%)

69 (95.8%)

0.99

None invasive

20 (4.9%)

17 (5%)

3 (4.2%)

AJCC stage

0.635

 0–1

61 (14.9%)

52 (15.4%)

9 (12.5%)

 2

195 (47.7%)

160 (47.5%)

35 (48.6%)

 3

121 (29.6%)

101 (30%)

20 (27.8%)

 4

32 (7.8%)

24 (7.1%)

8 (11.1%)

T

0.857

 0–1

115 (31.1%)

95(28.2%)

20(27.8%)

 2

229 (56%)

190(56.4%)

39(54.2%)

 3

31 (7.6%)

26(7.7%)

5(6.9%)

 4

25 (6.1%)

20(5.9%)

5(6.9%)

 Unknown

9 (2.2%)

6(1.8%)

3(4.2%)

N

0.397

 0

166(40.6%)

140(41.5%)

26(36.1%)

 1

110(26.9%)

89(26.4%)

21(29.2%)

 2

64(15.6%)

52(15.4%)

12(16.7%)

 3

63(15.4%)

53(15.7%)

10(13.9%)

 Unknown

6(1.5%)

3(0.9%)

3(4.2%)

M

0.253

 0

377 (92.2%)

313 (92.9%)

64 (88.9%)

 1

32 (7.8%)

24 (7.1%)

8 (11.1%)

ER status

0.132

 Positive

259 (63.3%)

219 (65%)

40 (55.6%)

 Negative

150 (36.7%)

118 (35%)

32 (44.4%)

PR status

0.231

 Positive

208(50.9%)

176 (52.2%)

32 (44.4%)

 Negative

201(49.1%)

161 (47.8%)

40 (55.6%)

HER2 status

< 0.001

 Positive

148(36.2%)

142 (42.1%)

6 (8.3%)

 Negative

257(62.8%)

191 (56.7%)

66 (91.7%)

 Unknown

4(1.0%)

4 (1.2%)

0 (0%)

Ki67 status

0.010

 ≥ 15%

338 (82.6%)

271 (80.4%)

67 (93.1%)

 < 15%

71 (17.4%)

66 (19.6%)

5 (6.9%)

Molecular subtype

< 0.001

 Luminal A

43 (10.5%)

39 (11.6%)

4 (5.6%)

 Luminal B

219 (53.5%)

183 (54.3%)

36 (50%)

 TNBC

77 (18.8%)

49 (14.5%)

28 (38.9%)

 HER2

70 (17.1%)

66 (19.6%)

4 (5.6%)